We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allegheny (ATI) to Exit Stainless Sheet Products Business
Read MoreHide Full Article
Allegheny Technologies Incorporated (ATI - Free Report) recently stated that it is exiting standard stainless sheet products. The company is streamlining its production footprint and investing in enhanced capabilities. Per the company, these initiatives will accelerate the execution of its high-value strategy, mainly in the defense and aerospace.
Notably, the company will exit standard stainless sheet products by the mid of 2021. The product line represented $445 million of revenues in 2019 with margins of less than 1%. By exiting this business, the company expects to achieve EBITDA margins of at least 15% within the Advanced Alloys and Solutions (“AA&S”) unit as the commercial aerospace end market recovers.
Additionally, Allegheny stated that it will consolidate the finishing operations by investing in its Vandergrift, PA. This will help the company create a competitive flow path focused on boosting production of high value, differentiated materials. It expects working capital releases to fund the $65-$85 million incremental investment over a period of three years.
Further, these restructuring activities are expected to enable the AA&S business to meaningfully improve its margin profile by lowering costs and improve revenue mix as the aerospace market recovers. The company expects the implementation of these actions to result in one-time charges of $25-$30 million, which will be incurred in the fourth quarter.
Shares of Allegheny have lost 28.8% in the past year compared with the industry’s 38.1% decline.
Zacks Rank & Key Picks
Allegheny currently carries a Zacks Rank #3 (Hold).
Impala Platinum has an expected earnings growth rate of 131.7% for fiscal 2021. Its shares have returned 29.5% in the past year.
BHP Group has an expected earnings growth rate of 32.4% for fiscal 2021. The company’s shares have gained 20.5% in the past year.
Silvercorp Metals has an expected earnings growth rate of 40% for fiscal 2021. The company’s shares have increased 13.2% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Allegheny (ATI) to Exit Stainless Sheet Products Business
Allegheny Technologies Incorporated (ATI - Free Report) recently stated that it is exiting standard stainless sheet products. The company is streamlining its production footprint and investing in enhanced capabilities. Per the company, these initiatives will accelerate the execution of its high-value strategy, mainly in the defense and aerospace.
Notably, the company will exit standard stainless sheet products by the mid of 2021. The product line represented $445 million of revenues in 2019 with margins of less than 1%. By exiting this business, the company expects to achieve EBITDA margins of at least 15% within the Advanced Alloys and Solutions (“AA&S”) unit as the commercial aerospace end market recovers.
Additionally, Allegheny stated that it will consolidate the finishing operations by investing in its Vandergrift, PA. This will help the company create a competitive flow path focused on boosting production of high value, differentiated materials. It expects working capital releases to fund the $65-$85 million incremental investment over a period of three years.
Further, these restructuring activities are expected to enable the AA&S business to meaningfully improve its margin profile by lowering costs and improve revenue mix as the aerospace market recovers. The company expects the implementation of these actions to result in one-time charges of $25-$30 million, which will be incurred in the fourth quarter.
Shares of Allegheny have lost 28.8% in the past year compared with the industry’s 38.1% decline.
Zacks Rank & Key Picks
Allegheny currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Impala Platinum Holdings Ltd. (IMPUY - Free Report) , BHP Group (BHP - Free Report) and Silvercorp Metals Inc. (SVM - Free Report) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Impala Platinum has an expected earnings growth rate of 131.7% for fiscal 2021. Its shares have returned 29.5% in the past year.
BHP Group has an expected earnings growth rate of 32.4% for fiscal 2021. The company’s shares have gained 20.5% in the past year.
Silvercorp Metals has an expected earnings growth rate of 40% for fiscal 2021. The company’s shares have increased 13.2% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>